PMTA Strategy and Outlook for Small and Mid-Sized Vape Companies: A Close Reading of the FDA's Recent Roundtable

LawMay's vape practice has long served the industry in both China and the United States. We recently attended, in full, an FDA roundtable on PMTA submissions for ENDS products, directed particularly at small and mid-sized companies. The session ran a full day, with candid and detailed exchanges between FDA scientists, reviewers, and industry participants. This note sets out what was said, so that smaller companies can avoid the common detours.

What the Roundtable Covered

The FDA worked through five modules.

Module 1: The overall PMTA framework and choosing a pathway. The FDA outlined the available routes — standard PMTA, the ENDS 510(k) substantial equivalence application, and exemption requests — explaining when each applies, the review timelines, and common errors in choosing among them. Many companies do not need a full PMTA but lose time and money because they do not understand the 510(k) requirements.

Module 2: The scientific standard for health risk assessment. The most technical portion of the day, covering test methods for the 18 HPHCs (harmful and potentially harmful constituents) in chemical characterization; standard operating procedures for aerosol analysis; design principles for toxicology studies (in vitro cytotoxicity, genotoxicity, systemic toxicity); GLP requirements for nonclinical studies; and product stability and shelf-life validation.

Module 3: The reasoning on public health impact. The FDA repeatedly emphasized that the "appropriate for the protection of public health" (APPH) standard cuts both ways. An applicant must argue both the potential benefit to current smokers (cessation rates, harm reduction) and the potential risk to non-users, particularly youth (initiation, dual use), and then assess the net population-level effect. The FDA singled out for criticism the practice of discussing only benefits while avoiding risks.

Module 4: Clinical study design and conduct. When human studies are required and how to design studies meeting FDA standards: abuse liability studies, actual use studies, switching studies, and perception and intention studies.

Module 5: Marketing plans and post-market surveillance. The part companies most often neglect. The FDA scrutinizes every design element of packaging and labeling; the technical implementation of age verification; the enforceability of retailer training programs; the adverse event reporting system; and post-market study commitments and timelines.

The session closed with two hours of Q&A in which the questions were pointed and the FDA's answers instructive.

Part One: What the FDA Wants to See — Three Fatal Errors

The director of the FDA's Office of Science put it plainly: most rejected applications fail not because the volume of data is inadequate, but because the data quality falls short, the chain of reasoning is broken, or the regulatory requirements have been misunderstood.

Fatal error one: a health risk assessment that is form over substance

Many companies submit risk assessments of only a few pages, amounting to "this product contains no tar and is less harmful than cigarettes." FDA reviewers were blunt: such empty statements are worthless.

What is required:

Complete chemical analysis — not merely the e-liquid formulation but the chemicals actually generated in the aerosol. The FDA requires testing of at least 18 HPHCs, including formaldehyde, acetaldehyde, acrolein, volatile organic compounds, and heavy metals.

Dose-response data — how harmful constituent yields change across power settings and use patterns.

A toxicology evidence chain — complete data from in vitro cell assays through animal models. "Not detected" is insufficient; detection limits, method validation, and quality control data are required.

Quantitative comparison with cigarettes — not "lower" but how much lower, against which reference cigarette, under what conditions.

The FDA stressed: if you claim harm reduction, you must show scientifically in what respects and to what degree.

Fatal error two: a one-sided reading of the public health standard

Many applicants assume that showing their product helps adult smokers quit is enough, ignoring the other side — youth protection.

The FDA used the image of a scale: potential benefit to adult smokers on one side, potential risk to non-users (especially youth) on the other. Only where the benefit side clearly outweighs the risk side can a product be authorized.

For flavored products, review is especially strict. Required:

Youth appeal assessment — not subjective judgment but consumer research data, focus group interviews, packaging test results.

Full review of marketing materials — social media, website, retail display, advertising placement; every touchpoint must be shown not to attract minors.

Use pattern projections — reasonable projections of usage rate changes by age cohort, based on market data.

One company asked: if my product is designed for adults, why worry about youth? The FDA's answer was direct: because in reality youth will encounter your product, and your responsibility is to show you took every reasonable measure to prevent it.

Fatal error three: a perfunctory marketing plan

Too many companies treat the marketing plan as a formality. FDA reviewers were explicit: the marketing plan is a core part of the application and is reviewed word by word.

Common deficiencies:

• Vague age verification — stating only that "age verification will be performed," without specifying the technical means, the verification flow, or what happens on failure.
• Unsupported packaging design — no explanation of why a particular color, pattern, or wording was chosen, or whether consumer perception testing was done.
• Hollow retailer management — no concrete training materials, agreement templates, or penalties for violations.
• An unworkable monitoring plan — promising to "monitor the market closely" without specifying frequency, data sources, or response to anomalies.

The FDA noted specifically: where a marketing plan is inconsistent with actual market conduct — stating no social media promotion while an Instagram account is highly active — that becomes a ground for refusal and may trigger enforcement.

Part Two: Practical Survival Strategies for Smaller Companies

The FDA expressed support for small companies repeatedly, but support is not leniency. Several strategies emerged.

Strategy one: consider the ENDS 510(k) substantial equivalence route first

If your product is a minor modification of an already-marketed product — nicotine concentration adjusted from 3% to 5%, a minor flavor reformulation, a packaging size change — do not go straight to a PMTA.

Advantages of the 510(k) route:

• substantially shorter review (typically a result within 90 days)
• 60–70% less data required
• much lower application cost
• a priority review channel for small-company 510(k) submissions

The key is identifying the right predicate. The FDA disclosed an important point: it is building a public database of authorized products to help companies find suitable predicates.

Strategy two: use the FDA's free support resources

Many smaller companies are unaware of the substantial free assistance available.

Pre-submission meetings. Before filing, you may request a meeting (usually by video) with the review team to discuss whether your testing plan meets requirements, which data are required and which may be waived, and the specifics of study design. The process takes roughly 90 days and produces written feedback. That feedback is not legally binding, but following it materially improves the odds of authorization.

The STDERR program (Small Tobacco Entity Development and Research), a technical assistance program for companies with under $10 million in annual revenue, which can help design GLP-compliant study protocols, interpret complex toxicology data, and assess the completeness of an application.

The FDA emphasized that using these resources does not affect review of your application or cause the agency to view your company differently. They are open and equally available.

Strategy three: three places not to economize

Smaller companies often cut costs where they should not, leading to refusal and the loss of everything invested.

A GLP-certified laboratory. The FDA was explicit that key toxicology studies must be conducted in GLP-certified facilities; data from non-certified laboratories may be disregarded. GLP costs are typically two to three times those of an ordinary laboratory, but the investment is necessary.

Stability testing of adequate duration. Many companies submit only accelerated stability data to save time. The FDA was clear: accelerated testing may supplement, but real-time data are required — a minimum of six months, with twelve or more recommended.

Complete aerosol chemistry. Do not test only a few principal constituents. All 18 HPHCs are required, tested repeatedly under different use conditions to show stability and reproducibility.

One small company asked whether it could cite others' research data. The FDA's answer: published scientific literature may be cited as background, but core product-specific data must come from actual testing of your own product.

Strategy four: consider engaging regulatory consultants

FDA reviewers said candidly that many applications are visibly written in-house without an understanding of regulatory logic. An experienced consultant can design the most economical and effective testing plan, avoid common format and content errors, organize materials in the language and logic the FDA expects, and prepare the discussion points for a pre-submission meeting. Consulting fees are not low, but authorization on the first attempt avoids the cost of resubmission.

Part Three: Regulatory Direction

Several subtle but important shifts in the FDA's focus were apparent.

Trend one: a materially higher bar for flavored products

Though not stated outright, the FDA's wording and emphasis indicate the threshold for non-tobacco flavors is rising. Data points mentioned:

• fewer than 5% of flavored products have cleared PMTA;
• nearly all menthol and fruit-flavored products have received Marketing Denial Orders;
• the exceptions are applications supplying unusually robust youth protection evidence.

If your line includes flavored products:

1. Do the youth prevention work properly: consumer perception research testing attitudes across age cohorts; packaging psychology analysis showing the design does not attract youth; and marketing channel controls detailing how advertising reaches adults only.
2. Prepare switching data. Evidence that your flavored product genuinely helps adult smokers switch from cigarettes, rather than attracting new users, may help.
3. Consider restructuring the product line. Where resources are limited, prioritize authorization for tobacco-flavored products, which have a markedly higher clearance rate (roughly 20–25%), before expanding to other flavors.

Trend two: stricter post-market surveillance

The FDA increasingly emphasizes ongoing oversight after authorization, and "conditional approval" came up repeatedly. That means you may be required to submit sales data and user research periodically; the FDA may withdraw authorization at any time if youth use rises; and the timeliness and completeness of adverse event reporting will be closely monitored.

A sound post-market system should include sales tracking (by age cohort, geography, and channel), social media monitoring (how your brand is discussed among youth), a rapid adverse event response mechanism, and periodic consumer research. These are compliance requirements and also necessary protection for your investment.

Trend three: the window for synthetic nicotine products is closing

The FDA noted that although synthetic nicotine products came within the Deeming Rule after amendment, many remain in a grey zone — and that enforcement will intensify with large-scale action in the coming months.

If your product uses synthetic nicotine: do not count on being overlooked; file a PMTA promptly. The FDA has been clear that synthetic nicotine products receive no exemption or favorable treatment for being non-tobacco-derived, and that the standard is identical to that for tobacco-derived nicotine.

Part Four: Pitfalls the FDA Called Out

Pitfall one: mixing and matching data

Reviewers cited a real example: a company used test data from three different production lots — chemical analysis from lot A, toxicology from lot B, stability from lot C. The application was refused outright, because it was impossible to determine which product the data represented.

The correct approach: designate one or a few representative lots as the test lots and conduct all key testing on them. Where data from different lots must be used, provide adequate lot-to-lot consistency validation.

Pitfall two: improper reliance on literature and third-party data

Asked whether published data could support an application, the FDA was clear: literature may be cited for background and scientific principle, but another product's test results cannot substitute for data on your own product. Even a "similar" product cannot be relied on directly, because small differences in formulation, design, and manufacturing can produce significantly different health risks. Extensive citation of other brands' public data will not be accepted.

Pitfall three: ignoring long-term health effects

Many applications address only acute toxicity and ignore chronic effects. The FDA emphasized that vapes are not single-use products; users may continue for years or decades. Required: subchronic toxicity studies (at least 90 days); chronic toxicity studies (six months or more recommended for products intended for long-term marketing); reproductive and developmental toxicity data; and a carcinogenicity assessment (which may rest on chemical composition and literature rather than a full two-year bioassay).

Pitfall four: a "split personality" in marketing materials

Reviewers emphasized the problem of saying one thing in the application and doing another in the market. A typical example: the application emphasizes helping adult smokers reduce cigarette use; social media is full of youth-oriented expression, trend culture, and emphasis on "flavor experience"; and retail displays place the product alongside candy and snacks.

The FDA stated that it investigates all of a company's marketing conduct — website, social media, retail points, advertising placements — and that any inconsistency with the application may be a ground for refusal.

Pitfall five: misunderstanding "substantial equivalence"

Many questions about the 510(k) route revealed misunderstanding. The FDA clarified: substantial equivalence does not mean identical; a degree of modification is permitted, but the modification must not raise different questions of public health. The determination is highly technical and not a matter of a company's own subjective sense that the products are "close enough."

Common misjudgments: assuming similar appearance means substantial equivalence (wrong — what matters is composition and performance); and assuming an improvement in some respect (longer battery life, say) cannot affect the analysis (wrong — if it changes use patterns, it may affect the health risk assessment).

Where you are unsure whether your product qualifies for 510(k), confirm through a pre-submission meeting rather than deciding on your own.

Part Five: Mindset and Long-Term Planning

A senior FDA reviewer closed with this:

"We are not in an adversarial posture with industry. Our objective is the same — making sure the products on the market help adult smokers reduce harm without damaging public health. But that requires solid scientific evidence. It cannot rest on luck, on guesswork, or on shortcuts."

A PMTA is not a one-shot exam

Many companies treat the PMTA as a single decisive test and approach it as a gamble. That framing is wrong. FDA review is an ongoing dialogue: where an application is deficient, the FDA may issue a deficiency letter giving an opportunity to supplement; even after a refusal, you may improve and resubmit based on the stated grounds; and after authorization you must continue to supply surveillance data and maintain communication with the agency.

This article addresses general legal questions only and does not constitute legal advice on any specific matter.